Cargando…

Stent Applications for Palliative Treatment in Advanced Stage Esophageal Cancers

METHODS: We examined cases of endoscopic stenting for palliative treatment of advanced stage esophageal cancers between January 2014 and July 2019. Age, gender, location of mass, adverse events, survival time, and stent type were evaluated. Outcomes of fully covered and uncovered self-expanding sten...

Descripción completa

Detalles Bibliográficos
Autores principales: Şentürk, Mustafa, Çakır, Murat, Yıldırım, Mehmet Aykut, Kişi, Ömer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8545594/
https://www.ncbi.nlm.nih.gov/pubmed/34707656
http://dx.doi.org/10.1155/2021/8034948
_version_ 1784590032516939776
author Şentürk, Mustafa
Çakır, Murat
Yıldırım, Mehmet Aykut
Kişi, Ömer
author_facet Şentürk, Mustafa
Çakır, Murat
Yıldırım, Mehmet Aykut
Kişi, Ömer
author_sort Şentürk, Mustafa
collection PubMed
description METHODS: We examined cases of endoscopic stenting for palliative treatment of advanced stage esophageal cancers between January 2014 and July 2019. Age, gender, location of mass, adverse events, survival time, and stent type were evaluated. Outcomes of fully covered and uncovered self-expanding stents were compared with regard to adverse events, including stent migration and occlusion. RESULTS: The mean age of the patients was 66.4 ± 1, 52 were male, and 8 were female. Patients were followed up for a mean of 133 days. The most common complication due to stenting was migration. 13 patients developed adverse events. Migration was the most common adverse event, occurring in 8 (13%) patients. Although the migration rate of fully covered stents was higher than uncovered stents, there was no statistically significant difference (p = 0.47). Stent occlusion was observed in 4 patients. In three cases, it was due to the tumor; an uncovered stent was placed again in these cases. Food-related occlusion developed in one patient. There was no statistical difference in terms of overall adverse event rate when comparing fully covered stents to uncovered stents (p = 0.68). CONCLUSION: Endoscopic stenting is a viable palliative method with low morbidity and mortality in experienced centers. Though there are relative advantages with covered versus uncovered stents in individual cases, the overall adverse event rate is low and relatively similar.
format Online
Article
Text
id pubmed-8545594
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-85455942021-10-26 Stent Applications for Palliative Treatment in Advanced Stage Esophageal Cancers Şentürk, Mustafa Çakır, Murat Yıldırım, Mehmet Aykut Kişi, Ömer Gastroenterol Res Pract Research Article METHODS: We examined cases of endoscopic stenting for palliative treatment of advanced stage esophageal cancers between January 2014 and July 2019. Age, gender, location of mass, adverse events, survival time, and stent type were evaluated. Outcomes of fully covered and uncovered self-expanding stents were compared with regard to adverse events, including stent migration and occlusion. RESULTS: The mean age of the patients was 66.4 ± 1, 52 were male, and 8 were female. Patients were followed up for a mean of 133 days. The most common complication due to stenting was migration. 13 patients developed adverse events. Migration was the most common adverse event, occurring in 8 (13%) patients. Although the migration rate of fully covered stents was higher than uncovered stents, there was no statistically significant difference (p = 0.47). Stent occlusion was observed in 4 patients. In three cases, it was due to the tumor; an uncovered stent was placed again in these cases. Food-related occlusion developed in one patient. There was no statistical difference in terms of overall adverse event rate when comparing fully covered stents to uncovered stents (p = 0.68). CONCLUSION: Endoscopic stenting is a viable palliative method with low morbidity and mortality in experienced centers. Though there are relative advantages with covered versus uncovered stents in individual cases, the overall adverse event rate is low and relatively similar. Hindawi 2021-10-18 /pmc/articles/PMC8545594/ /pubmed/34707656 http://dx.doi.org/10.1155/2021/8034948 Text en Copyright © 2021 Mustafa Şentürk et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Şentürk, Mustafa
Çakır, Murat
Yıldırım, Mehmet Aykut
Kişi, Ömer
Stent Applications for Palliative Treatment in Advanced Stage Esophageal Cancers
title Stent Applications for Palliative Treatment in Advanced Stage Esophageal Cancers
title_full Stent Applications for Palliative Treatment in Advanced Stage Esophageal Cancers
title_fullStr Stent Applications for Palliative Treatment in Advanced Stage Esophageal Cancers
title_full_unstemmed Stent Applications for Palliative Treatment in Advanced Stage Esophageal Cancers
title_short Stent Applications for Palliative Treatment in Advanced Stage Esophageal Cancers
title_sort stent applications for palliative treatment in advanced stage esophageal cancers
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8545594/
https://www.ncbi.nlm.nih.gov/pubmed/34707656
http://dx.doi.org/10.1155/2021/8034948
work_keys_str_mv AT senturkmustafa stentapplicationsforpalliativetreatmentinadvancedstageesophagealcancers
AT cakırmurat stentapplicationsforpalliativetreatmentinadvancedstageesophagealcancers
AT yıldırımmehmetaykut stentapplicationsforpalliativetreatmentinadvancedstageesophagealcancers
AT kisiomer stentapplicationsforpalliativetreatmentinadvancedstageesophagealcancers